Comment and Reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
Year: 2008
Type: article
Abstract: Dear Editor,With the introduction of new agents, outcomes for patients with advanced non-small cell lung cancer (NSCLC) have improved and clinicians now have several effective regimens from which t...
Source: Journal of Medical Economics
Authors: Jorge Arellano, Claudia Leteneux, Wioletta Kotowa, Ulrich Gatzemeier, Olaf Pirk, Anja Gabriel, David Heigener
Institution: Eli Lilly (United Kingdom)
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W1908498790